Filing summary: AcelRx Pharmaceuticals, Inc. 2019 Form 10-K
Issuer identification: The supplied filing is for AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), not Talphera, Inc. The reporting period is the fiscal year ended December 31, 2019; the report was filed March 16, 2020. Amounts below are U.S. dollars.
Business context and reporting period
AcelRx is a specialty pharmaceutical company developing and commercializing sublingual sufentanil products for acute pain in medically supervised settings. DSUVIA launched in the United States in Q1 2019; Zalviso is marketed in Europe by Grünenthal but had not received U.S. approval; and DZUVEO is approved in Europe, with no commercialization partner disclosed. The company reported one operating segment.
Financial performance and liquidity
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Total revenue | $2.289 million | $2.151 million |
| Product sales | $1.830 million | $0.825 million |
| Operating expenses | $56.494 million | $37.878 million |
| Operating loss | $54.205 million | $35.727 million |
| Net loss | $53.240 million | $47.149 million |
| Net loss per share | $0.67 | $0.81 |
| Cash used in operations | $51.180 million | $29.075 million |
- 2019 product sales comprised $0.377 million of DSUVIA and $1.453 million of Zalviso. Total revenue also included $0.459 million of contract and collaboration revenue; no DoD contract revenue was recognized in 2019.
- Cost of goods sold was $6.806 million against $2.289 million in total revenue, implying a gross loss of $4.517 million and an approximate gross margin of negative 197%. The filing notes that Zalviso supply prices to Grünenthal were below direct manufacturing costs.
- At year-end, cash and cash equivalents were $14.684 million, short-term investments $51.453 million, and combined cash and investments $66.137 million, down from $105.715 million. Working capital was $58.077 million.
- Long-term debt, including its current portion, was $25.147 million. The separate liability for monetized future royalties was $92.035 million. Total liabilities were $132.774 million, and stockholders’ equity was negative $41.418 million.
- Management said existing capital resources were expected to fund planned operations through the end of Q1 2021, but not until revenues could sustain operations; additional capital would be required over the longer term.
Material changes versus the prior comparable period
- Revenue increased 6% year over year, with product sales more than doubling as DSUVIA entered the market and Grünenthal’s Zalviso orders increased. Revenue remained small relative to operating costs.
- Operating expenses rose 49%, principally because selling, general and administrative expenses increased 117% to $45.027 million to support the DSUVIA launch. Research and development expenses fell 65% to $4.661 million as development work wound down and staff shifted toward commercialization.
- Net loss increased about 13%, while operating cash use rose from $29.075 million to $51.180 million. Cash and investments declined by $39.578 million.
- Cost of goods sold rose 71% to $6.806 million; the company recorded an approximately $1.0 million inventory write-down for early, shorter-dated DSUVIA batches.
- A revised estimate of payments due under the royalty monetization arrangement produced $1.337 million of non-cash interest income in 2019 versus $10.341 million of non-cash interest expense in 2018. The 2019 estimate change reduced net loss by $8.1 million; it was non-cash and depended on uncertain future European Zalviso sales.
- Quarterly Q4 2019 revenue was $0.475 million and net loss was $14.423 million, compared with Q4 2018 revenue of $0.613 million and net loss of $12.558 million.
Outlook, commentary, and principal risks
- No numerical revenue or earnings guidance was provided. Management expected continued significant losses in 2020 and identified DSUVIA adoption, launch spending, manufacturing costs, and Zalviso regulatory timing as important uncertainties.
- The timing of a U.S. Zalviso NDA resubmission depended on finalization of FDA opioid approval guidance. FDA concerns could include device errors and inadvertent tablet dispensing; further testing, label restrictions, or REMS requirements could delay or prevent approval.
- DSUVIA is restricted by a REMS program to certified medically supervised facilities and is not available through retail pharmacies or for outpatient use. Acceptance, facility certification, formulary access, reimbursement, pricing, and opioid-related scrutiny are material commercialization risks.
- Manufacturing relies on single or limited sources for key ingredients and components. The FDA had identified a deficiency in the API manufacturer’s drug master file that needed resolution before a U.S. submission could be approved. The company was also working toward automated DSUVIA packaging, with qualified production expected to begin in 2021.
- The Oxford loan requires at least $5 million of unrestricted cash and includes restrictive covenants; scheduled principal payments were to begin in July 2020. The loan is secured by substantially all assets, subject to stated intellectual-property exclusions.
- Subsequent events: On March 15, 2020, AcelRx agreed to acquire Tetraphase in a stock transaction, subject to closing conditions, and entered a co-promotion agreement for DSUVIA and XERAVA. The merger was expected to close in Q2 2020; former Tetraphase holders were expected to own approximately 14.6% of the combined company, excluding any share settlement of contingent value rights. AcelRx eliminated 30 positions, expected approximately $0.5 million in severance charges and estimated $8 million in annualized savings. These are post-year-end developments, not FY 2019 operating results.
- The filing discussed COVID-19 as a potential source of operating disruption, including reduced hospital access and procedures; its ultimate impact was uncertain at the filing date.
- The company reported an accumulated deficit of $398.106 million and recurring operating losses. Its auditor gave an unqualified opinion on the financial statements; management and the auditor concluded internal control over financial reporting was effective as of year-end.
Important facts for investors to verify
- Confirm the intended issuer: this filing identifies AcelRx, not Talphera.
- Track DSUVIA sales, facility certifications, reorder rates, returns, and whether product revenue can improve against substantial launch and manufacturing costs.
- Check cash burn and financing needs against the stated runway through Q1 2021, including the Oxford loan’s minimum-cash covenant and amortization schedule.
- Monitor FDA guidance and any Zalviso NDA resubmission, including resolution of device and API issues and possible added study or REMS requirements.
- Review the assumptions behind the royalty-monetization liability and potential contingent gain; the filing’s estimate of future payments was uncertain and not equivalent to cash available at year-end.
- Verify completion and terms of the Tetraphase merger, actual integration savings, dilution, and co-promotion performance; these developments occurred after the 2019 reporting period.